Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $86.77 Consensus Price Target from Analysts

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $86.7692.

Several analysts recently commented on PTGX shares. Citizens Jmp raised their target price on Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings upgraded Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, December 24th. Truist Financial raised their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and set a $82.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $79.73 on Friday. The stock has a market cap of $4.98 billion, a PE ratio of 128.60 and a beta of 2.26. The firm has a fifty day moving average price of $86.33 and a 200 day moving average price of $72.53. Protagonist Therapeutics has a 1 year low of $33.70 and a 1 year high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. As a group, equities analysts expect that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Activity at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 34,438 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total value of $2,840,446.24. Following the completion of the transaction, the chief executive officer owned 580,505 shares of the company’s stock, valued at approximately $47,880,052.40. This represents a 5.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Asif Ali sold 46,203 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the transaction, the chief financial officer owned 60,320 shares in the company, valued at $5,014,401.60. This represents a 43.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 165,167 shares of company stock worth $13,732,039 in the last 90 days. Corporate insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its holdings in shares of Protagonist Therapeutics by 18.7% during the second quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock worth $44,990,000 after buying an additional 128,171 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in Protagonist Therapeutics during the second quarter worth about $6,641,000. Voya Investment Management LLC boosted its position in Protagonist Therapeutics by 8.9% during the third quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after acquiring an additional 25,065 shares during the last quarter. Nan Fung Trinity HK Ltd. purchased a new stake in Protagonist Therapeutics during the 2nd quarter valued at about $7,464,000. Finally, Creative Planning raised its holdings in Protagonist Therapeutics by 74.3% in the 2nd quarter. Creative Planning now owns 30,204 shares of the company’s stock valued at $1,669,000 after acquiring an additional 12,871 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.